1288 related articles for article (PubMed ID: 33723270)
1. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue.
Zimniak M; Kirschner L; Hilpert H; Geiger N; Danov O; Oberwinkler H; Steinke M; Sewald K; Seibel J; Bodem J
Sci Rep; 2021 Mar; 11(1):5890. PubMed ID: 33723270
[TBL] [Abstract][Full Text] [Related]
2. Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants.
Thümmler L; Beckmann N; Sehl C; Soddemann M; Braß P; Bormann M; Brochhagen L; Elsner C; Hoertel N; Cougoule C; Ciesek S; Widera M; Dittmer U; Lindemann M; Horn PA; Witzke O; Kadow S; Kamler M; Gulbins E; Becker KA; Krawczyk A
Viruses; 2024 Mar; 16(4):. PubMed ID: 38675888
[TBL] [Abstract][Full Text] [Related]
3. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2
Good SS; Westover J; Jung KH; Zhou XJ; Moussa A; La Colla P; Collu G; Canard B; Sommadossi JP
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558299
[TBL] [Abstract][Full Text] [Related]
4. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M
Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962
[TBL] [Abstract][Full Text] [Related]
5. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
6. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.
Schloer S; Brunotte L; Mecate-Zambrano A; Zheng S; Tang J; Ludwig S; Rescher U
Br J Pharmacol; 2021 Jun; 178(11):2339-2350. PubMed ID: 33825201
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.
Jang Y; Shin JS; Lee MK; Jung E; An T; Kim UI; Kim K; Kim M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557278
[TBL] [Abstract][Full Text] [Related]
8. GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition.
Bestion E; Zandi K; Belouzard S; Andreani J; Lepidi H; Novello M; Rouquairol C; Baudoin JP; Rachid M; La Scola B; Mege JL; Dubuisson J; Schinazi RF; Mezouar S; Halfon P
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062337
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
10. Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.
Mahdi M; Hermán L; Réthelyi JM; Bálint BL
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409171
[TBL] [Abstract][Full Text] [Related]
11. Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model.
Péricat D; Leon-Icaza SA; Sanchez Rico M; Mühle C; Zoicas I; Schumacher F; Planès R; Mazars R; Gros G; Carpinteiro A; Becker KA; Izopet J; Strub-Wourgaft N; Sjö P; Neyrolles O; Kleuser B; Limosin F; Gulbins E; Kornhuber J; Meunier E; Hoertel N; Cougoule C
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362409
[TBL] [Abstract][Full Text] [Related]
12. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine.
Schloer S; Brunotte L; Goretzko J; Mecate-Zambrano A; Korthals N; Gerke V; Ludwig S; Rescher U
Emerg Microbes Infect; 2020 Dec; 9(1):2245-2255. PubMed ID: 32975484
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
14. Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use.
Foletto VS; da Rosa TF; Serafin MB; Hörner R
Eur J Clin Pharmacol; 2022 Oct; 78(10):1601-1611. PubMed ID: 35943535
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.
Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.
Shang C; Zhuang X; Zhang H; Li Y; Zhu Y; Lu J; Ge C; Cong J; Li T; Tian M; Jin N; Li X
Virol J; 2021 Feb; 18(1):46. PubMed ID: 33639976
[TBL] [Abstract][Full Text] [Related]
18. MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2.
Uemura K; Sasaki M; Sanaki T; Toba S; Takahashi Y; Orba Y; Hall WW; Maenaka K; Sawa H; Sato A
Sci Rep; 2021 Mar; 11(1):5376. PubMed ID: 33686154
[TBL] [Abstract][Full Text] [Related]
19. Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day.
Eugene AR
F1000Res; 2021; 10():477. PubMed ID: 36262792
[No Abstract] [Full Text] [Related]
20. Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?
Hoertel N
JAMA Netw Open; 2021 Nov; 4(11):e2136510. PubMed ID: 34779851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
